ETrade Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

ETrade Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$465K	Sell	3,260 -244	-7%	-$30.2K	0.01%	582
2020 Q2	$387K	Sell	3,504 -203	-5%	-$22.4K	0.01%	603
2020 Q1	$370K	Buy	3,707 +1,836	+98%	+$237K	0.01%	543
2019 Q4	$279K	Buy	+1,871	New	+$255K	0.01%	690
2016 Q1	–	Sell	-1,430	Closed	-$201K	–	469
2015 Q4	$201K	Sell	1,430 -548	-28%	-$75.9K	0.01%	423
2015 Q3	$262K	Buy	1,978 +357	+22%	+$61.5K	0.02%	382
2015 Q2	$285K	Buy	1,621 +297	+22%	+$53.3K	0.02%	365
2015 Q1	$229K	Sell	1,324 -48	-3%	-$8.24K	0.01%	369
2014 Q4	$225K	Sell	1,372 -83	-6%	-$13.8K	0.01%	420
2014 Q3	$234K	Sell	1,455 -684	-32%	-$105K	0.02%	400
2014 Q2	$315K	Sell	2,139 -268	-11%	-$37.2K	0.02%	297
2014 Q1	$334K	Sell	2,407 -571	-19%	-$85.9K	0.02%	263
2013 Q4	$377K	Buy	2,978 +4	+0.1%	+$414	0.03%	235
2013 Q3	$273K	Buy	2,974 +24	+0.8%	+$1.94K	0.03%	240
2013 Q2	$203K	Buy	+2,950	New	+$180K	0.02%	237

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

ETrade Capital Management's JAZZ Position: Q3 2020 in Review

ETrade Capital Management reduced its Jazz Pharmaceuticals (JAZZ) stake by 7% in Q3 2020, selling an estimated $30.2K and leaving 3,260 shares worth $465K. The position accounts for 0.01% of the portfolio, ranked #582.

ETrade Capital Management first reported a position in JAZZ in Q2 2013 and has held it in 15 quarters since. 390 funds tracked by Wall St. Rank hold JAZZ as of Q3 2020.

ETrade Capital Management held 3,260 shares of Jazz Pharmaceuticals worth $465K as of Q3 2020.
ETrade Capital Management sold 244 Jazz Pharmaceuticals shares in Q3 2020, an estimated $30.2K.
Jazz Pharmaceuticals made up 0.01% of ETrade Capital Management's portfolio in Q3 2020, its #582 holding.
ETrade Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
390 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.